Articles related to HEART FAILURE (HF)

A year‑in‑review article highlights major cardiovascular themes from 2025, including evolving approaches to hypertension, myocardial infarction management, and atrial fibrillation care.

Studies on fluid restriction in patients with HF are scarce, and most of the available studies are at high risk of bias. Although power is lacking, there is no evidence indicating that fluid restriction affects mortality or HF hospitalizations, but there is a signal of harm in terms of thirst distress.

“CHIP, especially non-DNMT3A CHIP, was independently associated with incident HF. Future research should explore the gene-specific mechanisms by which CHIP variants promote HF in humans.” — Study Authors, JAMA Cardiology

“Patients hospitalized for HFrEF in US clinical practice are at very high risk of poor clinical outcomes, even when prescribed quadruple medical therapy.” — Dr. Stephen J. Greene, Duke Clinical Research Institute

Continued collaboration across disciplines, enhanced focus on standardization, and investments in emerging technologies are imperative for bridging the gaps and driving innovation.

Beta-blocker use was not associated with reductions in all-cause mortality or cardiovascular mortality compared with the absence of beta-blocker therapy.